Smallpox - Pipeline Review, H1 2015

Published: Jan, 2015 | Pages: 86 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Smallpox - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Smallpox - Pipeline Review, H1 2015', provides an overview of the Smallpox's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Smallpox, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Smallpox and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Smallpox
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Smallpox and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Smallpox products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Smallpox pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons To Buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Smallpox
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Smallpox pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Smallpox Overview 8
Therapeutics Development 9
Pipeline Products for Smallpox - Overview 9
Pipeline Products for Smallpox - Comparative Analysis 10
Smallpox - Therapeutics under Development by Companies 11
Smallpox - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Unknown Stage Products 16
Smallpox - Products under Development by Companies 17
Smallpox - Companies Involved in Therapeutics Development 18
AlphaVax, Inc. 18
Bavarian Nordic A/S 19
CEL-SCI Corporation 20
Chimerix, Inc. 21
CJ CheilJedang Corp. 22
EpiVax, Inc. 23
Inovio Pharmaceuticals, Inc. 24
MacroGenics, Inc. 25
Nanotherapeutics, Inc. 26
Oncovir, Inc. 27
SIGA Technologies, Inc. 28
Symphogen A/S 29
TapImmune Inc. 30
Tonix Pharmaceuticals Holding Corp. 31
Smallpox - Therapeutics Assessment 32
Assessment by Monotherapy Products 32
Assessment by Target 33
Assessment by Mechanism of Action 35
Assessment by Route of Administration 37
Assessment by Molecule Type 39
Drug Profiles 41
brincidofovir - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
CEL-1000 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
cidofovir - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
CJ-50300 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
imatinib mesylate - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Monoclonal Antibodies for Infectious Disease - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
PL-801 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Poly-ICLC - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
small pox vaccine - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
smallpox (multivalent) vaccine - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
smallpox vaccine - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
smallpox vaccine - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
smallpox vaccine - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Sym-002 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
tecovirimat - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
TPIV-300 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
Smallpox - Recent Pipeline Updates 63
Smallpox - Dormant Projects 76
Smallpox - Discontinued Products 77
Smallpox - Product Development Milestones 78
Featured News & Press Releases 78
Jan 16, 2015: SIGA Technologies Appeals Judgment of Delaware Court of Chancery 78
Jan 07, 2015: Delaware Court of Chancery Issues Order Specifying Amount Of Lump Sum Expectation Damages Payable To PharmAthene; Total Award When Finalized, Including Pre-Judgment Interest, Attorneys' And Expert Witness Fees, Estimated To Be In Excess Of $190 Million 78
Dec 23, 2014: Chimerix Provides Recap of 2014 Events 78
Oct 04, 2014: Bavarian Nordic Announces Exercise of Contract Option by the U.S. Government for Continued Supply of IMVAMUNE Smallpox Vaccine 80
Sep 02, 2014: Chimerix and BARDA Announce Continued Partnership in the Development of Brincidofovir for Smallpox 80
Aug 26, 2014: Bavarian Nordic Receives Order from the Canadian Government to Supply IMVAMUNE Smallpox Vaccine 81
Aug 10, 2014: Delaware Court of Chancery Orders SIGA To Pay PharmAthene Lump Sum Expectation Damages 81
Jul 31, 2014: New Data on Chimerix's Brincidofovir Supports Safety and Antiviral Activity Against Multiple Life-Threatening DNA Viruses in Organ Transplant Recipients 82
Jul 08, 2014: Chimerix Announces Three Abstracts to be Presented at the 2014 World Transplant Congress 83
Apr 22, 2014: Bavarian Nordic Announces Execution of Option on Freeze-Dried IMVAMUNE 84
Appendix 85
Methodology 85
Coverage 85
Secondary Research 85
Primary Research 85
Expert Panel Validation 85
Contact Us 85
Disclaimer 85

List of Tables
Number of Products under Development for Smallpox, H1 2015 9
Number of Products under Development for Smallpox - Comparative Analysis, H1 2015 10
Number of Products under Development by Companies, H1 2015 12
Comparative Analysis by Late Stage Development, H1 2015 13
Comparative Analysis by Clinical Stage Development, H1 2015 14
Comparative Analysis by Early Stage Development, H1 2015 15
Comparative Analysis by Unknown Stage Development, H1 2015 16
Products under Development by Companies, H1 2015 17
Smallpox - Pipeline by AlphaVax, Inc., H1 2015 18
Smallpox - Pipeline by Bavarian Nordic A/S, H1 2015 19
Smallpox - Pipeline by CEL-SCI Corporation, H1 2015 20
Smallpox - Pipeline by Chimerix, Inc., H1 2015 21
Smallpox - Pipeline by CJ CheilJedang Corp., H1 2015 22
Smallpox - Pipeline by EpiVax, Inc., H1 2015 23
Smallpox - Pipeline by Inovio Pharmaceuticals, Inc., H1 2015 24
Smallpox - Pipeline by MacroGenics, Inc., H1 2015 25
Smallpox - Pipeline by Nanotherapeutics, Inc., H1 2015 26
Smallpox - Pipeline by Oncovir, Inc., H1 2015 27
Smallpox - Pipeline by SIGA Technologies, Inc., H1 2015 28
Smallpox - Pipeline by Symphogen A/S, H1 2015 29
Smallpox - Pipeline by TapImmune Inc., H1 2015 30
Smallpox - Pipeline by Tonix Pharmaceuticals Holding Corp., H1 2015 31
Assessment by Monotherapy Products, H1 2015 32
Number of Products by Stage and Target, H1 2015 34
Number of Products by Stage and Mechanism of Action, H1 2015 36
Number of Products by Stage and Route of Administration, H1 2015 38
Number of Products by Stage and Molecule Type, H1 2015 40
Smallpox Therapeutics - Recent Pipeline Updates, H1 2015 63
Smallpox - Dormant Projects, H1 2015 76
Smallpox - Discontinued Products, H1 2015 77